This article is more than 5 years old. Information may no longer be current.

ACC late-breaking clinical trials announced

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American College of Cardiology announced the lineup of late-breaking clinical trials scheduled for presentation at its 2017 Scientific Session, including the first CV outcome trials for PCSK9 inhibitors.

The ACC Scientific Session will be held March 17-19 in Washington, D.C.

The ACC stated in a press release that 23 presentations were selected as late-breakers, including:

• FOURIER, an assessment of the effect of the PCSK9 inhibitor evolocumab (Repatha, Amgen) on CV events in high-risk patients. Results of EBBINGHAUS, a cognitive study of patients in the FOURIER trial, will also be presented.
• SPIRE 1 and SPIRE 2, trials which show the safety and CV event efficacy of the PCSK9 inhibitor bococizumab (Pfizer). Pfizer recently announced it is ending the development of the agent.
• SURTAVI, the first trial comparing transcatheter aortic valve replacement with a self-expanding bioprosthesis (CoreValve, Medtronic) compared with surgical AVR in patients at intermediate surgical risk.
• EINSTEIN CHOICE, comparing rivaroxaban (Xarelto, Janssen Pharmaceuticals) vs. aspirin for extended treatment of venous thromboembolism, and GEMINI-ACS-1, comparing the two agents in patients with ACS on background P2Y12 inhibition therapy.
• COMPARE-ACUTE, which looks at fractional-flow-reserve-guided acute complete revascularization vs. culprit lesion-only treatment among patients with STEMI and multivessel disease.
• DECISION CTO, comparing results of drug-eluting stents vs. optimal medical therapy in patients with coronary chronic total occlusion.
• ABSORB III 2-year outcomes comparing an everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular) vs. a metallic DES in patients with CAD.
• RE-CIRCUIT, which studied the safety and efficacy of uninterrupted anticoagulation with dabigatran (Pradaxa, Boehringer Ingelheim) vs. warfarin in patients with atrial fibrillation undergoing catheter ablation.
• SPAIN, which assessed closed-loop stimulation in patients with recurrent reflex vasovagal syncope.
• LEVO-CTS, a study of levosimendan (Tenax Therapeutics) in patients with left ventricular systolic dysfunction undergoing cardiac surgery with cardiopulmonary bypass.
• RESOLVE and SAVORY will have registry results regarding subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic aortic valves.
• VISION, in which the relationship between high-sensitivity troponin T measurements and 30-day mortality after noncardiac surgery was assessed.

Cardiology Today and Cardiology Today’s Intervention will report live from the sessions. Visit Healio.com/Cardiology during the sessions for breaking news, videos, perspective from experts in the field on major results and announcements, and more.